Exclusive Summary

• - Low IP risk: Mesalazine is an old molecule and conventional 500 mg enteric-coated tablets face minimal patent barriers globally.
• - Strong, steady demand: ~7 million IBD patients worldwide with 3–4 million UC; 80–90% use 5-ASA at some point.
• - Clear standard-of-care role: International guidelines recommend mesalazine as first-line for mild-to-moderate UC (2–4 g/day dosing).
• - High-volume product: Maintenance dosing translates to ~1,100–1,750 tablets (500 mg) per patient-year, driving multi‑billion tablet annual demand.
• - Cost and compliance leverage: EU filing plan strengthens regulatory credibility; generics typically cut prices by 50–80% vs brands, aiding access and tenders.